medwireNews: Once-weekly tirzepatide superior to placebo for maintaining weight loss in people with obesity without diabetes, indicate findings from the SURMOUNT-4 trial.
10-10-2023 | Obesity | Editor's Choice | News
10-10-2023 | Obesity | Editor's Choice | News
medwireNews: Once-weekly tirzepatide superior to placebo for maintaining weight loss in people with obesity without diabetes, indicate findings from the SURMOUNT-4 trial.